Brand Name | Status | Last Update |
---|---|---|
riabni | Biologic Licensing Application | 2024-02-26 |
rituxan | Biologic Licensing Application | 2025-01-06 |
rituxan hycela | Biologic Licensing Application | 2024-11-20 |
ruxience | Biologic Licensing Application | 2024-10-10 |
truxima | Biologic Licensing Application | 2024-12-20 |
Expiration | Code | ||
---|---|---|---|
rituximab, Rituxan, Genentech, Inc. | |||
2026-09-27 | Orphan excl. | ||
rituximab / hyaluronidase human, Rituxan Hycela, Genentech, Inc. | |||
2024-06-22 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 397 | 922 | 272 | 21 | 118 | 1526 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 177 | 335 | 89 | 11 | 31 | 549 |
B-cell lymphoma | D016393 | — | — | 177 | 335 | 82 | 5 | 40 | 543 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 131 | 305 | 88 | 4 | 42 | 494 |
Leukemia | D007938 | — | C95 | 117 | 229 | 52 | 8 | 30 | 386 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 100 | 180 | 47 | 5 | 26 | 315 |
Lymphoid leukemia | D007945 | — | C91 | 89 | 182 | 45 | 9 | 25 | 312 |
Follicular lymphoma | D008224 | — | C82 | 78 | 152 | 69 | 1 | 22 | 279 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 60 | 146 | 29 | 1 | 7 | 210 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 15 | 20 | 32 | 21 | 35 | 117 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 32 | 38 | 1 | — | 2 | 59 |
Hematologic neoplasms | D019337 | — | — | 18 | 17 | 1 | — | 1 | 31 |
Myelodysplastic syndromes | D009190 | — | D46 | 9 | 19 | 2 | — | 3 | 28 |
Myeloid leukemia acute | D015470 | — | C92.0 | 10 | 15 | 3 | — | — | 25 |
Myeloid leukemia | D007951 | — | C92 | 9 | 18 | 1 | — | — | 24 |
Preleukemia | D011289 | — | — | 8 | 15 | 2 | — | 2 | 23 |
Graft vs host disease | D006086 | — | D89.81 | 4 | 16 | 3 | — | 2 | 23 |
Plasmablastic lymphoma | D000069293 | — | C83.3 | 12 | 17 | 1 | — | — | 23 |
Large-cell lymphoma immunoblastic | D016400 | — | — | 12 | 17 | 1 | — | — | 23 |
Anemia | D000740 | EFO_0004272 | D64.9 | 2 | 11 | 5 | — | 4 | 20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 21 | 17 | — | — | 1 | 33 |
Plasma cell neoplasms | D054219 | — | — | 14 | 12 | — | — | 1 | 24 |
T-cell lymphoma | D016399 | — | — | 11 | 12 | — | — | 2 | 20 |
Hairy cell leukemia | D007943 | — | C91.4 | 7 | 13 | — | — | 2 | 18 |
Central nervous system neoplasms | D016543 | — | — | 10 | 10 | — | — | 1 | 17 |
Intraocular lymphoma | D064090 | — | — | 8 | 10 | — | — | 1 | 15 |
Lymphomatoid granulomatosis | D008230 | — | C83.8 | 8 | 12 | — | — | — | 15 |
T-cell lymphoma peripheral | D016411 | — | — | 6 | 7 | — | — | 3 | 13 |
Aids-related lymphoma | D016483 | EFO_1001365 | — | 4 | 8 | — | — | — | 12 |
Aplastic anemia | D000741 | — | D61.9 | 2 | 7 | — | — | 2 | 11 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | — | — | — | 2 | 3 |
Squamous cell carcinoma | D002294 | — | — | 2 | — | — | — | — | 2 |
Retinal diseases | D012164 | — | H35.9 | 1 | — | — | — | 1 | 2 |
Transplantation | D014180 | — | — | 1 | — | — | — | — | 1 |
Disease | D004194 | EFO_0000408 | R69 | 1 | — | — | — | — | 1 |
Sclerosing cholangitis | D015209 | EFO_0004268 | K83.01 | 1 | — | — | — | — | 1 |
Cholangitis | D002761 | HP_0030151 | K83.0 | 1 | — | — | — | — | 1 |
Immunoglobulin g4-related disease | D000077733 | — | D89.84 | 1 | — | — | — | — | 1 |
Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | 1 | — | — | — | — | 1 |
Treatment-resistant depressive disorder | D061218 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 3 | 3 |
Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | — | 2 | 2 |
Human influenza | D007251 | EFO_0007328 | J11.1 | — | — | — | — | 2 | 2 |
Hemoglobin sc disease | D006450 | EFO_1001797 | D57.2 | — | — | — | — | 1 | 1 |
Hemoglobin c disease | D006445 | — | D58.2 | — | — | — | — | 1 | 1 |
Depression | D003863 | — | F33.9 | — | — | — | — | 1 | 1 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 1 | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 1 | 1 |
Uveitis | D014605 | EFO_1001231 | H20.9 | — | — | — | — | 1 | 1 |
Drug common name | Rituximab |
INN | rituximab |
Description | Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein.
|
Classification | Antibody |
Drug class | monoclonal antibodies: chimeric, tumors as target |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >1L6X:A|IMMUNOGLOBULIN GAMMA-1 HEAVY CHAIN CONSTANT REGION
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL
>1L6X:B|Minimized B-domain of Protein A Z34C
FNMQCQRRFYEALHDPNLNEEQRNAKIKSIRDDC |
PDB | 1L6X, 2OSL, 4KAQ, 6VJA, 6Y90 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201576 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB00073 |
UNII ID | 4F4X42SYQ6 (ChemIDplus, GSRS) |